guest ::
| Home > Publications database > Intercellular pathways of cancer treatment-related cardiotoxicity and their therapeutic implications: the paradigm of radiotherapy. > print |
| Home > Publications database > Intercellular pathways of cancer treatment-related cardiotoxicity and their therapeutic implications: the paradigm of radiotherapy. > print |
| 001 | 291634 | ||
| 005 | 20250825134235.0 | ||
| 024 | 7 | _ | |a 10.1016/j.pharmthera.2024.108670 |2 doi |
| 024 | 7 | _ | |a pmid:38823489 |2 pmid |
| 024 | 7 | _ | |a 0163-7258 |2 ISSN |
| 024 | 7 | _ | |a 1879-016X |2 ISSN |
| 024 | 7 | _ | |a altmetric:165245374 |2 altmetric |
| 037 | _ | _ | |a DKFZ-2024-01458 |
| 041 | _ | _ | |a English |
| 082 | _ | _ | |a 610 |
| 100 | 1 | _ | |a Logotheti, Stella |0 P:(DE-HGF)0 |b 0 |e First author |
| 245 | _ | _ | |a Intercellular pathways of cancer treatment-related cardiotoxicity and their therapeutic implications: the paradigm of radiotherapy. |
| 260 | _ | _ | |a Amsterdam [u.a.] |c 2024 |b Elsevier Science |
| 336 | 7 | _ | |a article |2 DRIVER |
| 336 | 7 | _ | |a Output Types/Journal article |2 DataCite |
| 336 | 7 | _ | |a Journal Article |b journal |m journal |0 PUB:(DE-HGF)16 |s 1721043240_17124 |2 PUB:(DE-HGF) |x Review Article |
| 336 | 7 | _ | |a ARTICLE |2 BibTeX |
| 336 | 7 | _ | |a JOURNAL_ARTICLE |2 ORCID |
| 336 | 7 | _ | |a Journal Article |0 0 |2 EndNote |
| 500 | _ | _ | |a #EA:E041# / Biomedical Physics in Radiation Oncology, German Cancer Research Center (DKFZ), Heidelberg, Germany |
| 520 | _ | _ | |a Advances in cancer therapeutics have improved patient survival rates. However, cancer survivors may suffer from adverse events either at the time of therapy or later in life. Cardiovascular diseases (CVD) represent a clinically important, but mechanistically understudied complication, which interfere with the continuation of best-possible care, induce life-threatening risks, and/or lead to long-term morbidity. These concerns are exacerbated by the fact that targeted therapies and immunotherapies are frequently combined with radiotherapy, which induces durable inflammatory and immunogenic responses, thereby providing a fertile ground for the development of CVDs. Stressed and dying irradiated cells produce 'danger' signals including, but not limited to, major histocompatibility complexes, cell-adhesion molecules, proinflammatory cytokines, and damage-associated molecular patterns. These factors activate intercellular signaling pathways which have potentially detrimental effects on the heart tissue homeostasis. Herein, we present the clinical crosstalk between cancer and heart diseases, describe how it is potentiated by cancer therapies, and highlight the multifactorial nature of the underlying mechanisms. We particularly focus on radiotherapy, as a case known to often induce cardiovascular complications even decades after treatment. We provide evidence that the secretome of irradiated tumors entails factors that exert systemic, remote effects on the cardiac tissue, potentially predisposing it to CVDs. We suggest how diverse disciplines can utilize pertinent state-of-the-art methods in feasible experimental workflows, to shed light on the molecular mechanisms of radiotherapy-related cardiotoxicity at the organismal level and untangle the desirable immunogenic properties of cancer therapies from their detrimental effects on heart tissue. Results of such highly collaborative efforts hold promise to be translated to next-generation regimens that maximize tumor control, minimize cardiovascular complications, and support quality of life in cancer survivors. |
| 536 | _ | _ | |a 315 - Bildgebung und Radioonkologie (POF4-315) |0 G:(DE-HGF)POF4-315 |c POF4-315 |f POF IV |x 0 |
| 588 | _ | _ | |a Dataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de |
| 650 | _ | 7 | |a Big data |2 Other |
| 650 | _ | 7 | |a Cancer |2 Other |
| 650 | _ | 7 | |a Cancer therapy |2 Other |
| 650 | _ | 7 | |a Cardiooncology |2 Other |
| 650 | _ | 7 | |a Cardiovascular diseases |2 Other |
| 650 | _ | 7 | |a Intercellular pathways |2 Other |
| 650 | _ | 7 | |a Multidisciplinary research |2 Other |
| 650 | _ | 7 | |a Multimodal omics |2 Other |
| 650 | _ | 7 | |a Radiotherapy |2 Other |
| 650 | _ | 7 | |a Radiotherapy-induced CVDs |2 Other |
| 650 | _ | 7 | |a Systems medicine |2 Other |
| 700 | 1 | _ | |a Pavlopoulou, Athanasia |b 1 |
| 700 | 1 | _ | |a Rudsari, Hamid Khoshfekr |b 2 |
| 700 | 1 | _ | |a Galow, Anne-Marie |b 3 |
| 700 | 1 | _ | |a Kafalı, Yağmur |b 4 |
| 700 | 1 | _ | |a Kyrodimos, Efthymios |b 5 |
| 700 | 1 | _ | |a Giotakis, Aris I |b 6 |
| 700 | 1 | _ | |a Marquardt, Stephan |b 7 |
| 700 | 1 | _ | |a Velalopoulou, Anastasia |b 8 |
| 700 | 1 | _ | |a Verginadis, Ioannis I |b 9 |
| 700 | 1 | _ | |a Koumenis, Constantinos |b 10 |
| 700 | 1 | _ | |a Stiewe, Thorsten |b 11 |
| 700 | 1 | _ | |a Zoidakis, Jerome |b 12 |
| 700 | 1 | _ | |a Balasingham, Ilangko |b 13 |
| 700 | 1 | _ | |a David, Robert |b 14 |
| 700 | 1 | _ | |a Georgakilas, Alexandros G |b 15 |
| 773 | _ | _ | |a 10.1016/j.pharmthera.2024.108670 |g Vol. 260, p. 108670 - |0 PERI:(DE-600)1500663-3 |p 108670 |t Pharmacology & therapeutics |v 260 |y 2024 |x 0163-7258 |
| 856 | 4 | _ | |u https://inrepo02.dkfz.de/record/291634/files/1-s2.0-S0163725824000901-main.pdf |
| 856 | 4 | _ | |u https://inrepo02.dkfz.de/record/291634/files/1-s2.0-S0163725824000901-main.pdf?subformat=pdfa |x pdfa |
| 909 | C | O | |o oai:inrepo02.dkfz.de:291634 |p VDB |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 0 |6 P:(DE-HGF)0 |
| 913 | 1 | _ | |a DE-HGF |b Gesundheit |l Krebsforschung |1 G:(DE-HGF)POF4-310 |0 G:(DE-HGF)POF4-315 |3 G:(DE-HGF)POF4 |2 G:(DE-HGF)POF4-300 |4 G:(DE-HGF)POF |v Bildgebung und Radioonkologie |x 0 |
| 914 | 1 | _ | |y 2024 |
| 915 | _ | _ | |a Nationallizenz |0 StatID:(DE-HGF)0420 |2 StatID |d 2023-10-21 |w ger |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0300 |2 StatID |b Medline |d 2023-10-21 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0199 |2 StatID |b Clarivate Analytics Master Journal List |d 2023-10-21 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1050 |2 StatID |b BIOSIS Previews |d 2023-10-21 |
| 915 | _ | _ | |a WoS |0 StatID:(DE-HGF)0113 |2 StatID |b Science Citation Index Expanded |d 2023-10-21 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0150 |2 StatID |b Web of Science Core Collection |d 2023-10-21 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1030 |2 StatID |b Current Contents - Life Sciences |d 2023-10-21 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1120 |2 StatID |b BIOSIS Reviews Reports And Meetings |d 2023-10-21 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0160 |2 StatID |b Essential Science Indicators |d 2023-10-21 |
| 915 | _ | _ | |a JCR |0 StatID:(DE-HGF)0100 |2 StatID |b PHARMACOL THERAPEUT : 2022 |d 2023-10-21 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0200 |2 StatID |b SCOPUS |d 2023-10-21 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0600 |2 StatID |b Ebsco Academic Search |d 2023-10-21 |
| 915 | _ | _ | |a Peer Review |0 StatID:(DE-HGF)0030 |2 StatID |b ASC |d 2023-10-21 |
| 915 | _ | _ | |a IF >= 10 |0 StatID:(DE-HGF)9910 |2 StatID |b PHARMACOL THERAPEUT : 2022 |d 2023-10-21 |
| 920 | 1 | _ | |0 I:(DE-He78)E041-20160331 |k E041 |l Med. Physik in der Radioonkologie |x 0 |
| 920 | 0 | _ | |0 I:(DE-He78)E041-20160331 |k E041 |l Med. Physik in der Radioonkologie |x 0 |
| 980 | _ | _ | |a journal |
| 980 | _ | _ | |a VDB |
| 980 | _ | _ | |a I:(DE-He78)E041-20160331 |
| 980 | _ | _ | |a UNRESTRICTED |
| Library | Collection | CLSMajor | CLSMinor | Language | Author |
|---|